Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Expands By 104.6%

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 162,797 shares, a growth of 104.6% from the June 15th total of 79,560 shares. Based on an average daily volume of 263,099 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.8% of the company’s stock are sold short.

Qualigen Therapeutics Price Performance

Shares of AIXC opened at $0.99 on Wednesday. The stock’s fifty day moving average price is $1.25. Qualigen Therapeutics has a 12-month low of $0.90 and a 12-month high of $8.81. The company has a market capitalization of $20.04 million, a PE ratio of -0.15 and a beta of 0.49.

Qualigen Therapeutics (NASDAQ:AIXC) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.79) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.